Answers are grounded in this paper and cite their sources.
This Viewpoint describes how policies shaping cannabis commercialization constitute a modifiable exposure and, thus, may influence psychiatric risk and suggests mitigation strategies.
No takes yet. Share an insight, caveat, or question.
Gilman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: